Revista Mexicana de Ortopedia Pediátrica

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista Mexicana de Ortopedia Pediátrica >Year 2018, Issue 2

Segura MJG, Ríos RG, Blanco LA
Experience with the use of bisphosphonates in osteogenesis imperfecta
Rev Mex Ortop Ped 2018; 20 (2)

Language: Español
References: 21
Page: 80-85
PDF: 121.33 Kb.

[Full text - PDF]


The treatment of patients with osteogenesis imperfecta through the administration of bisphosphonates has been shown to improve the rate of bone mineralization assessed by densitometry, as well as the decrease in fracture episodes during the first year of treatment. The primary objective of this study is to demonstrate the effectiveness of the different bisphosphonates that have been administered in patients with. Material and methods: A cross-sectional study of patients with OI assessed and treated by the use of bisphosphonates in a period between March 2004 and November 2015. Different variables such as gender, age, type of OI according to the classification of Sillence, type of bisphosphonate, treatment time, bone mineral density, number of fractures and homeostasis of calcium, phosphate, alkaline phosphatase, among others, were subjected to statistical evaluation by paired t test. All the data were collected and submitted to study using the SPSS 2® system. Results: Three study groups were defined according to the type of bisphosphonate used. It was observed that patients treated with Zolendronic acid significantly increased bone mineralization (p ‹ 0.001) and significantly reduced the episodes of fractures during the first year of treatment (p ‹ 0.001) with respect to patients treated with risendronate and alendronate, respectively. Conclusions: Patients with osteogenesis imperfecta treated by the administration of bisphosphonates have been shown to improve bone mineral density and decrease the recurrence of fractures. It was determined that the efficacy of zolendronic acid was superior to that shown by both risendronate and alendronate. This will help to determine more effective treatment plans in the medium and long term for patients with OI.

Key words: Osteogenesis imperfecta, bone mineral density, bisphosphonates, calcium homeostasis, bone densitometry.

>Journals >Revista Mexicana de Ortopedia Pediátrica >Year 2018, Issue 2
 Search   Advanced 

· Journal Index 
· Links 
Copyright 2010